The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Overcoming cellular barriers for RNA therapeutics
Abstract
RNA-based therapeutics, such as small-interfering (siRNAs), microRNAs (miRNAs), antisense oligonucleotides (ASOs), aptamers, synthetic mRNAs and CRISPR-Cas9, have great potential to target a large part of the currently undruggable genes and gene products and to generate entirely new therapeutic paradigms in disease, ranging from cancer to pandemic influenza to Alzheimer's disease. However, for these RNA modalities to reach their full potential, they first need to overcome a billion years of evolutionary defenses that have kept RNAs on the outside of cells from invading the inside of cells. Overcoming the lipid bilayer to deliver RNA into cells has remained the major problem to solve for widespread development of RNA therapeutics, but recent chemistry advances have begun to penetrate this evolutionary armor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As an emerging programmable gene interference technique, siRNA offers high specificity and flexibility in targeting the diseased human genome [236].”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [236]
In the citing paper
“Many obstacles still exist despite the rise in studies on delivery platforms, including toxicity and the precise distribution of mRNA to extrahepatic organs [13, 14].”
From Exosome for mRNA delivery: Strategies and therapeutic applications (2024) · cites this paper as [13]
In the citing paper
“Independent of the administration route, several evolutionary barriers are designed to prevent any intrusion of foreign nucleic acids and thus limit the delivery of exogenous mRNA [74].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [74]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“With the development of chemical modifications on RNA molecules, modified siRNA are reported to remain intact for long durations under circulation, which provides the possibility of delivering siRNA without the shielding of nanoparticles.[19, 75, 76]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Doherty, G. J., & McMahon, H. T. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081307.110540 · Cited by 3,075
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Flagged first, then by citations
Research works printed but not linked: 2
- Rich, A. in Horizons In Biochemistry (eds. Kasha, M. & Pullman, B.) 103–126 (Academic Press, New York, 1962).
- Cummings, R. & McEver, R. in Essentials of Glycobiology. 2nd edn. (eds. Varki, A. et al.) Chapter 31 (Cold Spring Harbor (NY); Cold Spring Harbor Laboratory Press, 2009).
Cited by
Sorted by citations
Items 201–300 of 1,000
Strategies for Efficient Genome Editing Using CRISPR-Cas9
Farboud, B., Severson, A. F., & Meyer, B. J. (2018) · Genetics · doi:10.1534/genetics.118.301775 · Cited by 66
TRAIL-based gene delivery and therapeutic strategies
Zhong, H., Wang, H., Li, J., & Huang, Y. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0287-8 · Cited by 74
Nanoencapsulated Dietary Polyphenols for Cancer Prevention and Treatment: Successes and Challenges
Tabrez, S. S. M., Jabir, N. R., Adhami, V. M., Khan, M. I., Moulay, M., Kamal, M. A., & Mukhtar, H. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0398 · Cited by 75
Overcoming the challenges of tissue delivery for oligonucleotide therapeutics
Gökirmak, T., Nikan, M., Wiechmann, S., Prakash, T. P., Tanowitz, M., & Seth, P. P. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.04.010 · Cited by 73
Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy
Li, C., Yang, T., Weng, Y., Zhang, M., Zhao, D., Guo, S., Hu, B., Shao, W., Wang, X., Hussain, A., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.05.051 · Cited by 69
The potential of long noncoding RNA therapies
Mercer, T. R., Munro, T. P., & Mattick, J. S. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.01.008 · Cited by 72
Immunological barriers to haematopoietic stem cell gene therapy
Charlesworth, C. T., Hsu, I., Wilkinson, A. C., & Nakauchi, H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00698-0 · Cited by 71
Huang, J., & Xiao, K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081586 · Cited by 73
Nanoparticles-mediated CRISPR/Cas9 delivery: Recent advances in cancer treatment
Aghamiri, S., Talaei, S., Ghavidel, A. A., Zandsalimi, F., Masoumi, S., Hafshejani, N. H., & Jajarmi, V. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101533 · Cited by 70
A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs
Bogaert, B., Sauvage, F., Guagliardo, R., Muntean, C., Nguyen, V. P., Pottie, E., Wels, M., Minnaert, A., Rycke, R. M. D., Yang, Q., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.009 · Cited by 69
Precision RNA base editing with engineered and endogenous effectors
Pfeiffer, L. S., & Stafforst, T. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01927-0 · Cited by 68
Nucleic acids delivering nucleic acids
Catuogno, S., Esposito, C. L., Condorelli, G., & de Franciscis, V. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.006 · Cited by 68
Wang, H., Miao, W., Wang, F., & Cheng, Y. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00246 · Cited by 67
Tomé‐Carneiro, J., Fernández-Alonso, N., Tomás‐Zapico, C., Visioli, F., Iglesias‐Gutiérrez, E., & Dávalos, A. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.04.003 · Cited by 72
Fluid protein condensates for bio-inspired applications
Harrington, M. J., Mezzenga, R., & Miserez, A. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00133-6 · Cited by 72
New approaches to genetic therapies for cystic fibrosis
Boyd, A. C., Guo, S., Huang, L., Kerem, B., Oren, Y. S., Walker, A. J., & Hart, S. L. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.12.012 · Cited by 70
Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy
Yi, K., Kong, H., Lao, Y., Li, D., Mintz, R. L., Fang, T., Chen, G., Tao, Y., Li, M., & Ding, J. (2023) · Advanced Materials · doi:10.1002/adma.202300665 · Cited by 66
Current Progress of Virus-mimicking Nanocarriers for Drug Delivery
Somiya, M., Liu, Q., & Kuroda, S. (2017) · Nanotheranostics · doi:10.7150/ntno.21723 · Cited by 65
Serum Nuclease Susceptibility of mRNA Cargo in Condensed Polyplexes
Yen, A., Cheng, Y., Sylvestre, M., Gustafson, H. H., Puri, S., & Pun, S. H. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00134 · Cited by 69
Xu, C., Li, D., Cao, Z., Xiong, M., Yang, X., & Wang, J. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b00657 · Cited by 65
ROS-Activatable siRNA-Engineered Polyplex for NIR-Triggered Synergistic Cancer Treatment
Zhang, M., Weng, Y., Cao, Z., Guo, S., Hu, B., Lu, M., Guo, W., Yang, T., Li, C., Yang, X., et al. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c06614 · Cited by 66
Long Noncoding RNAs in Atherosclerosis and Vascular Injury
Pierce, J. B., & Feinberg, M. W. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314222 · Cited by 64
siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses
Sajid, M. I., Moazzam, M., Cho, Y., Kato, S., Xu, A., Way, J. J., Lohan, S., & Tiwari, R. K. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c01239 · Cited by 64
Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications
Yan, Y., Liu, S., Wen, J., He, Y., Duan, C., Nabavi, N., Ashrafizadeh, M., Sethi, G., Liu, L., & Ma, R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02463-y · Cited by 71
Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development
Andersson, S., Antonsson, M., Elebring, M., Jansson‐Löfmark, R., & Weidolf, L. O. G. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.030 · Cited by 64
Illuminating RNA trafficking and functional delivery by extracellular vesicles
de Voogt, W. S., Tanenbaum, M. E., & Vader, P. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.017 · Cited by 65
Feng, H., Li, Z., Xie, W., Wan, Q., Guo, Y., Chen, J., Wang, J., & Pei, X. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.132867 · Cited by 64
Tang, L., Zhang, R., Wang, Y., Zhang, X., Yang, Y., Zhao, B., & Yang, L. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.11.013 · Cited by 63
Nutter, C. A., & Kuyumcu‐Martinez, M. N. (2017) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1459 · Cited by 67
MiR-519d suppresses breast cancer tumorigenesis and metastasis via targeting MMP3
Chu, C., Liu, X., Bai, X., Zhao, T., Wang, M., Xu, R., Li, M., Hu, Y., Li, W., Yang, L., et al. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.22849 · Cited by 63
Kim, S. M., Shin, S. C., Kim, E. E., Kim, S., Park, K., Oh, S. J., & Jang, M. (2018) · ACS Nano · doi:10.1021/acsnano.8b01670 · Cited by 63
Virus-Inspired Function in Engineered Protein Cages
Edwardson, T. G. W., & Hilvert, D. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b03705 · Cited by 64
Emerging Concepts and Challenges in Rheumatoid Arthritis Gene Therapy
Deviatkin, A. A., Vakulenko, Y. A., Akhmadishina, L. V., Tarasov, V. V., Beloukhova, M. I., Zamyatnin, A. A., & Lukashev, A. N. (2020) · Biomedicines · doi:10.3390/biomedicines8010009 · Cited by 63
LncRNAs in Cancer: From garbage to Junk
Aprile, M., Katopodi, V., Leucci, E., & Costa, V. (2020) · Cancers · doi:10.3390/cancers12113220 · Cited by 63
Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy
Yoo, Y. J., Lee, C. H., Park, S. H., & Lim, Y. T. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.047 · Cited by 62
Advances and prospects of RNA delivery nanoplatforms for cancer therapy
Attia, M. S., Kijanka, G. S., Nguyen, N., Zhang, J., & An, H. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.09.009 · Cited by 64
Cerium oxide nanoparticle delivery of microRNA-146a for local treatment of acute lung injury
Niemiec, S. M., Hilton, S. A., Wallbank, A. M., Azeltine, M., Louiselle, A. E., Elajaili, H. B., Allawzi, A. M., Xu, J., Mattson, C., Dewberry, L. C. K., et al. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102388 · Cited by 62
Anwar, S., Mir, F., & Yokota, T. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041130 · Cited by 65
Control of backbone chemistry and chirality boost oligonucleotide splice switching activity
Pachamuthu, K., McClorey, G., Shimizu, M., Kothari, N., Alam, R., Iwamoto, N., Kumarasamy, J., Bommineni, G. R., Bezigian, A., Chivatakarn, O., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac018 · Cited by 62
Self-Assembled Cationic β-Cyclodextrin Nanostructures for siRNA Delivery
Singh, R. P., Hidalgo, T., Cazade, P., Darcy, R., Cronin, M. F., Dorin, I., O’Driscoll, C. M., & Thompson, D. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01307 · Cited by 62
Small interfering RNA from the lab discovery to patients' recovery
Caillaud, M., Madani, M. E., & Massaad-Massade, L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.032 · Cited by 60
Deciphering the roles of lncRNAs in breast development and disease
Richard, J. L. C., & Eichhorn, P. J. A. (2018) · Oncotarget · doi:10.18632/oncotarget.24591 · Cited by 62
Polycatechol Mediated Small Interfering RNA Delivery for the Treatment of Ulcerative Colitis
Fan, Q., Yang, Z., Li, Y., Cheng, Y., & Li, Y. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202101646 · Cited by 59
Insights into the development of chemical probes for RNA
Morgan, B. S., Forte, J. E., & Hargrove, A. E. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky718 · Cited by 57
RNA-based therapeutics for colorectal cancer: Updates and future directions
Liu, J., & Guo, B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104550 · Cited by 61
Non-coding RNAs in gastric cancer
Xie, S., Chang, Y., Jin, H., Yang, F., Xu, Y., Yan, X., Lin, A., Shu, Q., & Zhou, T. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.022 · Cited by 58
Wang, L., Wang, Z., Pan, Y., Chen, S., Fan, X., Li, X., Chen, G., Ma, Y., Cai, Y., Zhang, J., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c25180 · Cited by 58
Targeting materials and strategies for RNA delivery
Lin, L., Su, K., Cheng, Q., & Liu, S. (2023) · Theranostics · doi:10.7150/thno.87316 · Cited by 61
Enhancing siRNA efficacy in vivo with extended nucleic acid backbones
Yamada, K., Hariharan, V. N., Caiazzi, J., Miller, R., Ferguson, C. M., Sapp, E., Fakih, H. H., Tang, Q., Yamada, N., Furgal, R. C., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02336-7 · Cited by 60
Porciani, D., Cardwell, L. N., Tawiah, K. D., Alam, K. K., Lange, M. J., Daniëls, M. A., & Burke, D. H. (2018) · Nature Communications · doi:10.1038/s41467-018-04691-x · Cited by 58
Gene Silencing via PDA/ERK2‐siRNA‐Mediated Electrospun Fibers for Peritendinous Antiadhesion
Liu, S., Wu, F., Gu, S., Wu, T., Chen, S., Chen, S., Wang, C., Huang, G., Jin, T., Cui, W., et al. (2018) · Advanced Science · doi:10.1002/advs.201801217 · Cited by 58
Marras, A. E., Vieregg, J., Ting, J., Rubien, J. D., & Tirrell, M. (2019) · Polymers · doi:10.3390/polym11010083 · Cited by 64
Brome mosaic virus-like particles as siRNA nanocarriers for biomedical purposes
Núñez-Rivera, A., Fournier, P. G. J., Arellano, D. L., Rodríguez‐Hernández, A. G., Vázquez-Duhalt, R., & Cadena-Nava, R. D. (2020) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.11.28 · Cited by 58
Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs
Kokkinos, J., Ignacio, R. M. C., Sharbeen, G., Boyer, C. A., Gonzales‐Aloy, E., Goldstein, D., Initiative, A. P. C. G., McCarroll, J. A., & Phillips, P. A. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119742 · Cited by 57
RNA-mediated therapies in myotonic dystrophy
Overby, S. J., Cerro-Herreros, E., Llamusí, B., & Artero, R. D. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.08.004 · Cited by 57
Light‐Inducible Exosome‐Based Vehicle for Endogenous RNA Loading and Delivery to Leukemia Cells
Huang, L., Gu, N., Zhang, X., & Wang, D. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201807189 · Cited by 57
Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy
Lee, J. W., Choi, J., Choi, Y., Kim, K., Yang, Y., Kim, S. H., Yoon, H. Y., & Kwon, I. C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.040 · Cited by 57
Overcoming Pharmaceutical Bottlenecks for Nucleic Acid Drug Development
Lu, M., Xing, H., Zheng, A., Huang, Y., & Liang, X. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.2c00464 · Cited by 60
Molecular functions and specific roles of circRNAs in the cardiovascular system
Holdt, L. M., Kohlmaier, A., & Teupser, D. (2018) · Non-coding RNA Research · doi:10.1016/j.ncrna.2018.05.002 · Cited by 55
Duncan, R. (2017) · Journal of drug targeting · doi:10.1080/1061186x.2017.1358729 · Cited by 57
A Mirror Image Fluorogenic Aptamer Sensor for Live-Cell Imaging of MicroRNAs
Zhong, W., & Sczepanski, J. T. (2019) · ACS Sensors · doi:10.1021/acssensors.9b00252 · Cited by 55
Innovative developments and emerging technologies in RNA therapeutics
Halloy, F., Biscans, A., Bujold, K. E., Debacker, A. J., Hill, A. C., Lacroix, A., Luige, O., Strömberg, R., Sundström, L., Vogel, J., et al. (2022) · RNA Biology · doi:10.1080/15476286.2022.2027150 · Cited by 57
Lipid Nanoparticles for Nucleic Acid Delivery Beyond the Liver
Saber, N., Sentí, M. E., & Schiffelers, R. M. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.106 · Cited by 61
Aptamer-iRNAs as Therapeutics for Cancer Treatment
Soldevilla, M. M., Meraviglia-Crivelli, D., Menon, A. P., & Pastor, F. (2018) · Pharmaceuticals · doi:10.3390/ph11040108 · Cited by 54
Zickler, A. M., Liang, X., Gupta, D., Mamand, D. R., Luca, M. D., Corso, G., Errichelli, L., Hean, J., Sen, T., Elsharkasy, O. M., et al. (2024) · Advanced Science · doi:10.1002/advs.202407619 · Cited by 55
Therapeutic applications of synthetic nucleic acid aptamers
Poolsup, S., & Kim, C. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.05.004 · Cited by 53
RNA epigenetics and cardiovascular diseases
Dorn, L. E., Tual‐Chalot, S., Stellos, K., & Accornero, F. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.03.010 · Cited by 53
A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
Wong, D. J., Park, D., Park, S. J., Haller, C. A., Chen, J., Dai, E., Liu, L., Mandhapati, A. R., Eradi, P., Dhakal, B., et al. (2021) · Blood · doi:10.1182/blood.2020009428 · Cited by 53
Drug Discovery Perspectives of Antisense Oligonucleotides
Kim, Y. (2023) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2023.001 · Cited by 52
Yu, H., Iscaro, J., Dyett, B., Zhang, Y., Seibt, S., Martínez, N. P., White, J., Drummond, C. J., Bozinovski, S., & Zhai, J. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c08729 · Cited by 53
A review of hyaluronic acid-based therapeutics for the treatment and management of arthritis
Walvekar, P., Luliński, P., Kumar, P., Aminabhavi, T. M., & Choonara, Y. E. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130645 · Cited by 52
Design and assessment of engineered CRISPR–Cpf1 and its use for genome editing
Li, B., Zeng, C., & Dong, Y. (2018) · Nature Protocols · doi:10.1038/nprot.2018.004 · Cited by 50
Buntz, A., Killian, T., Schmid, D., Seul, H., Brinkmann, U., Ravn, J., Lindholm, M., Knoetgen, H., Haucke, V., & Mundigl, O. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1158 · Cited by 52
Ning, B., Yu, D., & Yu, A. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113638 · Cited by 53
Cell type–specific microRNA therapies for myocardial infarction
Liu, B., Wang, B., Zhang, X., Lock, R., Nash, T., & Vunjak-Novakovic, G. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd0914 · Cited by 53
Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics
de Vyver, T. V., Smedt, S. C. D., & Raemdonck, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114041 · Cited by 51
Towards the Clinical Application of Gene Therapy for Genetic Inner Ear Diseases
Lahlou, G., Calvet, C., Giorgi, M., Lecomte, M.-J., & Safieddine, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031046 · Cited by 57
Overcoming biological barriers by virus-like drug particles for drug delivery
Chen, Y., Bao, C., Duan, J., Xie, Y., & Lü, W.-L. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115134 · Cited by 51
Tang, L., Zhang, R., Wang, Y., Liu, M., Hu, D., Wang, Y., & Li, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.04.006 · Cited by 51
Anand, P., Zhang, Y., Patil, S., & Kaur, K. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02528 · Cited by 56
Lin, Y., Huang, Y., Yang, Y., Jiang, L., Xing, C., Li, J., Lü, C., & Yang, H. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c03746 · Cited by 51
Biocatalytic Synthesis of Antiviral Nucleosides, Cyclic Dinucleotides, and Oligonucleotide Therapies
Giesen, K. J. D. V., Thompson, M. J., Meng, Q., & Lovelock, S. L. (2022) · JACS Au · doi:10.1021/jacsau.2c00481 · Cited by 54
Template-independent enzymatic synthesis of RNA oligonucleotides
Wiegand, D. J., Rittichier, J., Meyer, E., Lee, H., Conway, N. J., Ahlstedt, D., Yurtsever, Z., Rainone, D., Kuru, E., & Church, G. M. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02244-w · Cited by 60
A siRNA-induced peptide co-assembly system as a peptide-based siRNA nanocarrier for cancer therapy
Li, W., Wang, D., Shi, X., Li, J., Ma, Y., Wang, Y., Li, T., Zhang, J., Zhao, R., Yu, Z., et al. (2018) · Materials Horizons · doi:10.1039/c8mh00392k · Cited by 50
Effect of surface charge on the size-dependent cellular internalization of liposomes
Sakai‐Kato, K., Yoshida, K., & Izutsu, K. (2019) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2019.01.004 · Cited by 52
Room-temperature preparation of coordination polymers for biomedicine
Wang, J., Wang, X., Wang, Y., Hu, X., Lian, J.-R., Guan, Y.-L., Chen, H., He, Y., & Wang, H. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213256 · Cited by 50
Ayyar, V. S., Song, D., Zheng, S., Carpenter, T., & Heald, D. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000805 · Cited by 51
Therapeutic strategies targeting AMPK-dependent autophagy in cancer cells
Yuan, W., Fang, W., Zhang, R., Lyu, H., Xiao, S., Guo, D. S., Ali, D. W., Michalak, M., Chen, X., Zhou, C., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2023.119537 · Cited by 53
Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges
Hofman, C. R., & Corey, D. R. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.09.005 · Cited by 56
Xu, R. F., Huang, L., Liu, J., Zhang, Y., Xu, Y., Li, R., Su, S., & Xu, X. (2023) · Small · doi:10.1002/smll.202305923 · Cited by 50
Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery
Haque, M. A., Shrestha, A., Mikelis, C. M., & Mattheolabakis, G. (2024) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2024.100283 · Cited by 52
Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided?
Haßel, S. K., & Mayer, G. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00400-6 · Cited by 49
Wang, K., Shang, F., Chen, D., Cao, T., Wang, X., Jiao, J., He, S., & Liang, X. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00777-9 · Cited by 50
Stealth Fluorescence Labeling for Live Microscopy Imaging of mRNA Delivery
Baladi, T., Nilsson, J. R., Gallud, A., Celauro, E., Gasse, C., Lévi-Acobas, F., Sarac, I., Hollenstein, M., Dahlén, A., Esbjörner, E. K., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00014 · Cited by 50
Liu, G., Carter, B., & Gifford, D. K. (2020) · Cell Systems · doi:10.1016/j.cels.2020.11.010 · Cited by 48
Advances in the design and delivery of RNA vaccines for infectious diseases
Lokras, A. G., Bobak, T. R., Baghel, S. S., Sebastiani, F., & Foged, C. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115419 · Cited by 52
Understanding the interactions between inorganic-based nanomaterials and biological membranes
Kang, Y., Liu, J., Jiang, Y., Yin, S., Huang, Z.-D., Zhang, Y., Wu, J., Chen, L., & Shao, L. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.030 · Cited by 50
Li, X., Bhullar, A. S., Binzel, D. W., & Guo, P. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114316 · Cited by 47
Helm, J., Schöls, L. J., & Hauser, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081708 · Cited by 50
Forenzo, C., & Larsen, J. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00439 · Cited by 48
Metadata
- Authors
- Dowdy, S. F.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Dowdy, Steven F
- ORCID
- Dowdy, Steven F
- Venue
- Nature Biotechnology
- Published
- 2017-02-27
- Volume
- 35
- Issue
- 3
- Pages
- 222-229
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2594133976
- Cited by
- 1,139
- References
- 105
- Citations by year
- 2026: 103 · 2025: 130 · 2024: 147 · 2023: 133 · 2022: 130 · 2021: 141 · 2020: 104 · 2019: 88 · 2018: 120 · 2017: 41
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- RNA therapeutics, RNA delivery, lipid bilayers, siRNA, microRNA, antisense oligonucleotides, aptamers, synthetic mRNA, CRISPR/Cas9
- MeSH terms
- RNAi Therapeutics, Animals, Cell Membrane, Humans, RNA, RNA Interference, Nanocapsules, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
